Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
VRDN

VRDN - Viridian Therapeutics, Inc. Stock Price, Fair Value and News

$28.67+0.26 (+0.92%)
Market Closed

23/100

VRDN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

23/100

VRDN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

VRDN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VRDN Price Action

Last 7 days

1.2%

Last 30 days

-4.7%

Last 90 days

-11.3%

Trailing 12 Months

81.3%

VRDN RSI Chart

VRDN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VRDN Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-8.55

Price/Sales (Trailing)

41.36

Price/Free Cashflow

-10.58

VRDN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

VRDN Fundamentals

VRDN Revenue

Revenue (TTM)

70.8M

Rev. Growth (Yr)

-98.16%

Rev. Growth (Qtr)

-99.81%

VRDN Earnings

Earnings (TTM)

-342.6M

Earnings Growth (Yr)

-50.96%

Earnings Growth (Qtr)

-247.86%

VRDN Profitability

Operating Margin

96.40%

Return on Equity

-47.44%

Return on Assets

-38.09%

Free Cashflow Yield

-9.45%

VRDN Investor Care

Shares Dilution (1Y)

25.43%

VRDN Alerts

  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202517.9M35.6M53.2M70.8M
2024000302.0K
20230000
20221.5M2.6M3.8M4.9M
20211.7M2.6M2.8M318.0K
20204.9M2.6M1.9M1.1M
20194.0M4.3M4.1M4.5M
20188.3M9.8M9.1M8.4M
20173.0M2.6M3.3M4.0M
20162.8M3.2M3.6M3.5M
20153.9M3.4M3.0M2.5M
20144.3M4.8M5.7M4.3M
201304.4M4.3M4.3M
20120004.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Viridian Therapeutics, Inc.

VRDN
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEviridiantherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES86

Viridian Therapeutics, Inc. Frequently Asked Questions

VRDN is the stock ticker symbol of Viridian Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Viridian Therapeutics, Inc. is 2.93 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, VRDN's PE ratio (Price to Earnings) is -8.55 and Price to Sales (PS) ratio is 41.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VRDN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Viridian Therapeutics, Inc. has provided -0.136 (multiply by 100 for percentage) rate of return.